Trial Profile
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Octreotide
- Indications Colon cancer; Gastric cancer; Gastrointestinal cancer; Lung cancer; Neuroendocrine carcinoma; Rectal cancer; Tumours
- Focus Therapeutic Use
- 19 Feb 2024 This study has been completed in Germany, according to European Clinical Trials Database record.
- 03 Jan 2024 Results published in the European Journal of Endocrinology
- 07 Feb 2023 Last checked against ClinicalTrials.gov record.